Tekmira to Present TKM-PLK1 Phase 1 Clinical Trial Results at AACR

[at noodls] – VANCOUVER, British Columbia, Feb. 4, 2013 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that … more

View todays social media effects on TKMR

View the latest stocks trending across Twitter. Click to view dashboard

See who Tekmira is hiring next, click here to view